Eli Lilly's experimental drug retatrutide demonstrated significant efficacy in the TRIUMPH-2 Phase 3 trial, helping patients with obesity and type 2 diabetes lose an average of 49.6 pounds. The results underscore the drug's potential to disrupt the metabolic health market as more than half of participants dropped below obesity BMI thresholds.
Positive Phase 3 trial results for retatrutide showing substantial weight loss and A1C reduction could significantly boost Lilly's obesity and diabetes franchise.